Early Experience with Human Papillomavirus Vaccine Introduction in the United States, Canada and Australia
Abigail Shefer, Lauri Markowitz, Shelley Deeks, Theresa Tam, Kathleen Irwin, Suzanne M Garland, Anne Schuchat
VACCINE | ELSEVIER SCI LTD | Published : 2008
Successful incorporation of a new vaccine into a nation's vaccination program requires addressing a number of issues, including: 1) establishing national recommendations; 2) assuring education of and acceptance by the public and medical community; 3) establishing and maintaining an appropriate infrastructure for vaccine delivery; 4) financing the vaccine and the program, in addition to political will. This article reviews the early experience with implementation of human papillomavirus (HPV) vaccination programs. It focuses on the United States of America and Canada and provides a brief report on Australia, where introduction is underway.
SMG: Advisory Board (Commonwealth Serum Laboratories, GlaxoSmithKline); Consultant (Merck and Co., Inc); Research Grants (Commonwealth Serum Laboratories, GlaxoSmithKline, Merck and Co., Inc.); Speakers Bureau (GlaxoSmithKline, Merck and Co., Inc); Travel Grants (Commonwealth Serum Laboratories, GlaxoSmithKline).